The consensus advice will be updated as new evidence emerges and will provide the structure for a more definitive guideline in the future.
“In the absence of a registration dossier, scientific experiments and case reports are helpful to provide some guidance to optimized dosing.
But as in this guidance, observational data obtained from clinical practice, which often includes information not included in scientific experiments or even early clinical trial data, such as treating patients with other comorbidities, taking multiple medications, and patient diversitycan be very helpful to clinical practice”, said senior author Jennifer H. Martin, MBChB, MA, PhD, FRACP, researchers at the University of Newcastle and the Director of the Australian Centre for Cannabis Clinical and Research Excellence.
Source: Medindia
